ORs for EBV-directed Abs with evidence of an association between clinical response and the Ab change between preinfusion and 3-month postinfusion (Ab3mo−Abpre) time points
| Array sequence . | Protein name . | Life cycle . | IgG/IgA . | Logistic regression P value . | P value (FDR) . | OR (95% CI) . |
|---|---|---|---|---|---|---|
| YP_001129484.1-113481-112483 | BGLF3 | Late lytic | IgA | .036 | .889 | 0.011 (0-0.564) |
| YP_001129510.1-165796-162410-2 | BALF2 | Early lytic | IgA | .036 | .889 | 0 (0-0.154) |
| AFY97950.1-104968-104363 | BBLF2/3 | Early lytic | IgA | .043 | .889 | 0 (0-0.324) |
| YP_001129486.1-115415-114405 | BGLF2 | Early lytic | IgG | .042 | .359 | 0.06 (0.002-0.681) |
| YP_001129505.1-153178-151769 | LF1 | Other/unknown | IgG | .045 | .359 | 0.036 (0.001-0.7) |
| YP_001129484.1-113481-112483 | BGLF3 | Late lytic | IgG | .046 | .359 | 0.075 (0.004-0.713) |
| Array sequence . | Protein name . | Life cycle . | IgG/IgA . | Logistic regression P value . | P value (FDR) . | OR (95% CI) . |
|---|---|---|---|---|---|---|
| YP_001129484.1-113481-112483 | BGLF3 | Late lytic | IgA | .036 | .889 | 0.011 (0-0.564) |
| YP_001129510.1-165796-162410-2 | BALF2 | Early lytic | IgA | .036 | .889 | 0 (0-0.154) |
| AFY97950.1-104968-104363 | BBLF2/3 | Early lytic | IgA | .043 | .889 | 0 (0-0.324) |
| YP_001129486.1-115415-114405 | BGLF2 | Early lytic | IgG | .042 | .359 | 0.06 (0.002-0.681) |
| YP_001129505.1-153178-151769 | LF1 | Other/unknown | IgG | .045 | .359 | 0.036 (0.001-0.7) |
| YP_001129484.1-113481-112483 | BGLF3 | Late lytic | IgG | .046 | .359 | 0.075 (0.004-0.713) |
FDR correction method used was Benjamini and Hochberg. The table is ordered by P value (lowest to highest). Logistic regression P values < .05 were considered nominally significant for this analysis.